Sunyoung Lee, PhD, MS, oversees global regulatory strategy across all of BBOT’s clinical programs as Vice President, Regulatory Affairs. Prior to BBOT’s spinout from BridgeBio Pharma, she served as Senior Director, Global Regulatory Affairs at BridgeBio and focused on the global regulatory strategy for the company’s oncology assets.

Before BridgeBio, Sunyoung served as Global Regulatory Affairs Lead at Amgen, leading the BLA filing for IMDELLTRA, a DLL3targeting BiTE® immunotherapy approved for extensive stage small cell lung cancer. Earlier in her career, she was an assistant professor at the Sanford Burnham Prebys Medical Discovery Institute, focusing on tumor angiogenesis and vascular biology. Sunyoung holds an MS in Regulatory Science, Pharmacy from the University of Southern California (USC), completed her postdoctoral fellowship at the University of California, Los Angeles, earned her PhD in Gene Therapy & Virology from USC, and received her BA in Biochemistry from Yonsei University in Seoul, South Korea.